Bevacizumab-maly 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Bevacizumab 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Alymsys is a vascular endothelial growth factor inhibitor.
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
Vegzelma is a vascular endothelial growth factor inhibitor.
Drugs in the Pipeline
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
Drug Monograph Updates
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of October. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…